STOKStoke Therapeutics, Inc.同业对比
Stoke Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOK本股 | $1.8B#7 | — | 5.2x#9 | 9.8x#4 | 404.5%#3 | 92.3%#2 | -11.2%#4 | -2.0%#5 | — | — | 20.6%#6 | — |
| GENB | $2.0B#1 | — | 4.4x#6 | — | — | — | — | 0.0%#2 | — | — | — | — |
| RAPP | $2.0B#2 | — | 4.7x#8 | — | — | -42.4%#10 | — | -26.4%#9 | — | — | — | — |
| AGIO | $2.0B#3 | — | 1.9x#3 | 36.4x#8 | 48.0%#6 | -161.3%#11 | -873.9%#10 | -40.3%#10 | — | — | — | — |
| PRGO | $1.9B#4 | — | 0.7x#1 | 0.4x#1 | -2.8%#10 | -729.7%#12 | -26.4%#5 | -56.7%#11 | -20.9%#3 | 4#1 | -30.5%#10 | 8.5%#1 |
| ZYME | $1.9B#5 | — | 23.1x#10 | 17.6x#6 | 38.9%#8 | 33.9%#5 | -87.3%#6 | -100.9%#12 | — | — | 65.5%#5 | — |
| BHVN | $1.8B#6 | — | 148.4x#14 | — | — | 12.7%#7 | — | -6045.0%#15 | — | — | -18.4%#8 | — |
| SEPN | $1.8B#8 | — | 4.6x#7 | 39.0x#9 | 4174.5%#1 | 31.9%#6 | -148.6%#8 | -12.6%#7 | — | — | 165.5%#3 | — |
| XNCR | $1.8B#9 | — | 3.5x#5 | 14.0x#5 | 13.7%#9 | 60.5%#4 | -141.4%#7 | -18.3%#8 | -31.5%#4 | — | 155.2%#4 | — |
| ANIP | — | 16.1x#1 | — | — | 43.8%#7 | 510.5%#1 | 12.6%#2 | 13.1%#1 | 16.9%#1 | — | -24.5%#9 | — |
| KLRA | $1.6B#10 | — | 1.5x#2 | — | — | — | — | 0.0%#2 | — | — | — | — |
| KARD | $1.6B#11 | — | 2.6x#4 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ETON | $1.6B#12 | — | 34.6x#11 | 20.1x#7 | 104.9%#5 | -20.4%#9 | -1.1%#3 | -9.9%#6 | -1.8%#2 | 4#1 | 220.3%#1 | — |
| ANAB | $1.6B#13 | — | 124.0x#13 | 6.7x#2 | 157.0%#4 | 90.9%#3 | 20.4%#1 | -103.8%#13 | — | — | 180.0%#2 | — |
| SNDX | $1.5B#14 | — | 102.1x#12 | 8.9x#3 | 627.8%#2 | 10.5%#8 | -158.4%#9 | -1890.2%#14 | -1205.8%#5 | — | 14.9%#7 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议